Project Grant R37CA297814
Award Date
1/10/25
Completion Date
12/31/29
Dollars Obligated
$580K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $300,000 to the University of California, Davis to conduct research on the epidemiology of the gut-liver axis and hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The goal is to identify novel bacteria, metabolites, and glycoproteins associated with HCC risk, particularly in the Latinx population who are underrepresented in current...
The National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,265,232 Project Grant to the Regents of the University of Michigan to develop a novel peptide-based multimer for early detection of hepatocellular carcinoma (HCC) using advanced imaging techniques. The project aims to identify specific peptide targets for HCC through single-cell RNA sequencing and create a multivalent peptide ligand that can detect cancer...
This Project Grant award of $165,883 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to support the research project "INFLAMMATION AND HEPATOCELLULAR CARCINOMA: A MULTIOMICS APPROACH TO IMPROVE EARLY DETECTION, CAUSAL INFERENCE, AND LIFESTYLE BASED PREVENTION". The primary awardee is Brigham & Women's Hospital Inc., a prominent academic medical center in Boston, Massachusetts. The research aims to: 1) Examine...
This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop novel, biologic RNA molecules that can modulate metabolism in hepatocellular carcinoma (HCC), the most common form of liver cancer. The University of California, Davis is the prime awardee, receiving $483,591 over the 5-year project period from August 1, 2024 to July 31, 2029. The key objectives are to: (1) design, clone, express, and...
This Project Grant award of $884,453.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a rapid, cost-effective point-of-care (POC) test for detecting the hepatitis C virus (HCV). The project, titled "Rapid Point of Care Hepatitis C Virus Detection Using a Long-Lasting Luminescent Cascade Signal Amplification," is being conducted by Brigham & Women's Hospital...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to study the role of tumor-associated plasmacytoid dendritic cells (TAPDC) in the tumor immune microenvironment of liver cancer or hepatocellular carcinoma (HCC) in the context of HIV infection. The $634,061 award to the University of Maryland, Baltimore aims to: 1) characterize how TAPDC reprogram the HCC tumor immune microenvironment, including the impact of HIV...
The National Cancer Institute (NCI) awarded a $436,472 R21 project grant to Cedars-Sinai Medical Center under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The objective is to investigate the performance of novel circulating biomarker digital scores for evaluating treatment response in hepatocellular carcinoma (HCC) patients. The research leverages two technologies - an HCC extracellular vesicle digital scoring assay and the GALAD serum protein-based scoring system - to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) aims to unveil a novel mechanism of oncovirus-induced carcinogenesis. The research team at Rutgers, The State University of New Jersey will conduct long-read sequencing on hepatitis B virus (HBV)-positive tumors and cell lines to map HBV integrations. The project will validate if HBV integration-bridged chromosomal translocations lead to enhancer hijacking, contributing to HBV-positive tumor...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of Columbia University in the City of New York, with a total funding of $687,679. The grant will fund research aimed at understanding and targeting transcriptional master regulators in hepatocellular carcinoma (HCC). The project seeks to computationally establish HCC transcriptional master regulators, validate their tumor cell-intrinsic functions...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $592,027 to Northwestern University to develop and validate a point-of-care molecular diagnostic test for active hepatitis C virus (HCV) infection. The key products and services to be delivered include: Development of the "DASH HCV" test that can rapidly detect HCV viral RNA from a simple finger-stick blood sample, without the...